Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

imageGilda Varricchi1,2imageGianenrico Senna3imageStefania Loffredo1,2imageDiego Bagnasco4imageMatteo Ferrando4 and imageGiorgio Walter Canonica5*
1Division of Clinical Immunology and Allergy, Department of Translational Medical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy
2Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
3Asthma Center and Allergy Unit, Verona University, General Hospital, Verona, Italy
4Allergy and Respiratory Diseases, DIMI Department of Internal Medicine, IRCCS AOU San Martino-IST, University of Genova, Genova, Italy
5Personalized Medicine Clinic Asthma and Allergy Humanitas Clinical and Research Center, Department of Biomedical Science, Humanitas University, Rozzano, Milano, Italy

Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89–92 of IL-5 that are critical for binding to IL-5 receptor α. Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (≥400 cells/μL) improved lung function, asthma control, and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma.


Download Article
 

 
 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Stallergenes Greer Announces Submission of New Drug Application for Pediatric Use of ACTAIR® in Japan https://t.co/cZDUfBE069
5hreplyretweetfavorite
Interasma RT @Aller_MD: FARE announces recipients of 2017 Investigator in Food Allergy Awards https://t.co/voT8AmGFmm
5hreplyretweetfavorite
Interasma RT @Aller_MD: “Strategies to Alter the Natural History of Childhood #Asthmahttps://t.co/4LFtauTtNw https://t.co/H8DdZsebZ2
5hreplyretweetfavorite
Interasma RT @Aller_MD: New Peanut Introduction Guidance https://t.co/ch5ltEOjgx https://t.co/LaGsIfjoMi
5hreplyretweetfavorite
Interasma Top story: European Commission considering leap into open-access publishing | S… https://t.co/KNBfbUmo3n, see more https://t.co/CpGiFuOOYd
11hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

InterAsma